Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Asset Writedowns and Impairment (2020 - 2025)

RxSight (RXST) has disclosed Asset Writedowns and Impairment for 6 consecutive years, with $616000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Asset Writedowns and Impairment rose 767.61% year-over-year to $616000.0, compared with a TTM value of $1.9 million through Dec 2025, up 378.22%, and an annual FY2025 reading of $1.9 million, up 378.22% over the prior year.
  • Asset Writedowns and Impairment was $616000.0 for Q4 2025 at RxSight, up from $66000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $1.8 million in Q2 2021 and bottomed at -$7000.0 in Q1 2021.
  • Average Asset Writedowns and Impairment over 5 years is $280950.0, with a median of $72000.0 recorded in 2022.
  • The sharpest move saw Asset Writedowns and Impairment plummeted 100.3% in 2023, then soared 16700.0% in 2024.
  • Year by year, Asset Writedowns and Impairment stood at $10000.0 in 2021, then surged by 2880.0% to $298000.0 in 2022, then tumbled by 49.33% to $151000.0 in 2023, then plummeted by 52.98% to $71000.0 in 2024, then soared by 767.61% to $616000.0 in 2025.
  • Business Quant data shows Asset Writedowns and Impairment for RXST at $616000.0 in Q4 2025, $66000.0 in Q3 2025, and $1.2 million in Q2 2025.